Sun Pharmaceutical Industries Ltd. et al. vs. Novo Nordisk A/S

Explore the PTAB proceeding IPR2024-00107 filed by Sun Pharmaceutical Industries Ltd. et al. on 2023-11-02. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Proceeding Overview

Proceeding Number

IPR2024-00107

Filing Date

2023-11-02

Accorded Filing Date

2023-11-02

Institution Decision Date

2024-05-28

Last Modified Date

2025-01-10

Proceeding Type

IPR

Termination Date

2025-01-10

Trial Status

Terminated-Settled

Parties & Counsel

Petitioner

Sun Pharmaceutical Industries Ltd. et al.

Represented By

Sodikoff, Brianet al

Patent Owner / Respondent

Novo Nordisk A/S

Represented By

Baughman, Jonet al

Tribunal & Venue

Tribunal

Patent Trial and Appeal Board (USPTO)

Technology Center

TC 1600 - Biotechnology & Organic Chemistry

Patent Information

1 Patent Involved

Respondent Application Number 15656042

Respondent Patent Number 10335462

External Links

Espacenet

Google Patents

Respondent Inventor Christine Bjoern Jensen

Respondent Tech Center TC 1600 - Biotechnology & Organic Chemistry

Address and Attorney/Agent Information

5 Registered Practitioners

Power of Attorney & Correspondence

Firm / Entity Name NOVO NORDISK INC. - INTELLECTUAL PROPERTY DEPARTMENT

Customer Number 23650

Address 800 Scudders Mill Road, Plainsboro, NJ, 08536, UNITED STATES

Attorney / Agent Information

Reg #	Name	Phone
56129	Wesley Nicolas	609-786-5418
62124	Leon Lum	609-786-4172
63996	Elizabeth Dingess-Hammond	317-433-3689
64519	Jianjie Hu	609-786-4129
74995	Kathryn Jones	804-426-7196

Proceeding Documents

143

Termination Decision: Post-DI Settlement TERMINATE

2025-01-10 FILING PARTY: BOARD

Download

Order: On Protective Orders and Motions to Seal ORDER

2025-01-10 FILING PARTY: BOARD

Download

Order: Order on Motions to Expunge ORDER

2025-01-10 FILING PARTY: BOARD

Download

3001

Exhibit 3001 Exhibit

2024-05-28 FILING PARTY: BOARD

Download

Granting Institution of Inter Partes Review 35 U.S.C. § 314 Granting Motion for Joinder 35 U.S.C. § 315(c); 37 C.F.R. § 42.122 OTHER

2024-05-28 FILING PARTY: BOARD

Download

Sun Pharmaceutical Industries Ltd. et al. vs. Novo Nordisk A/S

Proceeding Overview

Parties & Counsel

Petitioner

Sun Pharmaceutical Industries Ltd. et al.

Represented By

Patent Owner / Respondent

Novo Nordisk A/S

Represented By

Tribunal & Venue

Patent Information

Address and Attorney/Agent Information

Power of Attorney & Correspondence

Attorney / Agent Information

Proceeding Documents

Termination Decision: Post-DI Settlement TERMINATE

Order: On Protective Orders and Motions to Seal ORDER

Order: Order on Motions to Expunge ORDER

Exhibit 3001 Exhibit

Granting Institution of Inter Partes Review 35 U.S.C. § 314 Granting Motion for Joinder 35 U.S.C. § 315(c); 37 C.F.R. § 42.122 OTHER

PETITIONERS' REPLY TO PATENT OWNER'S FURTHER AUTHORIZED REPLY OTHER

EX2031 - Email Exchange Between Counsel for Petitioner and Counsel for Patent Owner Regarding Request To File Stipulation Exhibit

Patent Owner's Further Authorized Reply OTHER

Updated Exhibit List May 1 NOTICE

EX1099 Sun Pharmaceutical Industries Ltd.’s and Sun Pharmaceutical Industries, Inc.’s Stipulation of Invalidity Contentions Exhibit

EX2028 - Excerpt of Opening Expert Report of Dr. John Bantle Regarding Invalidity of U.S. Patent No. 10,335,462, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del.) Exhibit

EX2030 - Excerpt of Opening Expert Report of Dr. Paul Dalby Regarding Invalidity of U.S. Patent No. 10,335,462, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del.) Exhibit

EX2029 - Excerpt of Opening Expert Report of William J. Jusko, Ph.D. Regarding Invalidity of U.S. Patent No. 10,335,462, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del.) Exhibit

Patent Owner's Sur-Reply OTHER

PETITIONERS REPLY TO PATENT OWNERS PRELIMINARY RESPONSE REPLYTOOPP

Oral Order, Novo Nordisk Inc. v. Rio Biopharmaceuticals Inc., No. 22-294 (CFC) (D. Del. March 13, 2024) Exhibit

EX2011 - U.S. Patent No. 8,114,833 Exhibit

EX2019 - Novo Nordisk Production Letter, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del. Oct. 17, 2023) [REDACTED] Exhibit

EX2004 - Stipulation and Order Regarding Trial of the MPI Ozempic Litigation, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC, Dkt. 245 (D. Del. Oct. 31, 2023) Exhibit

EX2007 - Excerpt of Transcript of Dec. 13, 2023 Claim Construction Hearing, Novo Nordisk Inc. v. Mylan Pharmaceuticals Inc., No. 23-101-CFC (D. Del. Dec. 13, 2023) Exhibit

EX2018 - Excerpt of Defendants' Second Supplemental Invalidity Contentions Regarding U.S. Patent Nos. 8,129,343; 8,536,122; 8,114,833; 8,920,383; 9,775,953; 9,457,154; and 10,335,462, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del. Jan. 12, 2024) [REDACTED] Exhibit

EX2001 - Excerpt of Defendants' Initial Invalidity Contentions Regarding U.S. Patent Nos. 8,129,343; 8,536,122; 8,114,833; 8,920,383; 9,775,953; 9,457,154; and 10,335,462, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del. Oct. 20, 2022) Exhibit

EX2020 - Compilation of Defendants' Production Letters, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del.) [REDACTED] Exhibit

EX2024 - Stipulation for Extension of Time, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC, Dkt. 309 (D. Del. Feb. 9, 2024) Exhibit

EX2023 - Notice of Service for Defendants' Supplemental Invalidity Contentions, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del. Nov. 6, 2023) Exhibit

EX2002 - Petition for Inter Partes Review, Mylan Pharms. Inc. v. Novo Nordisk A/S, IPR2023-00724, Pap.1 (Mar. 16, 2023) Exhibit

EX2009 - Joint Stipulation and Order Amending Scheduling Order, In re: Ozempic (Semaglutide) Patent Litigation, MDL No. 22-MD-03038-CFC, Dkt. 268 (D. Del. Dec. 1, 2023) Exhibit

EX2005 - Nov. 29, 2023 Email from E. Goldschlager to Counsel, re: IPR2023-00724 – Request for Conference Call Exhibit

EX2003 - Declaration of Sayem Osman Exhibit

EX2006 - Scheduling Order, Novo Nordisk Inc. v. Rio Biopharms., Inc., No. 1:22-cv-00294-CFC, Dkt. 22 (D. Del. June 30, 2022) Exhibit

EX2026 - Sun Pharmaceutical Industries Ltd.'s and Sun Pharmaceutical Industries Inc.'s Stipulation of Invalidity Contentions, Novo Nordisk Inc. v. Rio Biopharmaceuticals Inc., No. 22-cv-00294-CFC, Dkt. 275 (D. Del. Nov. 6, 2023) Exhibit

EX2022 - Notice of Service for Defendants' Initial Invalidity Contentions, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del. Oct. 20, 2022) Exhibit

EX2013 - Summons in a Civil Action, Sun Pharmaceutical Industries Ltd., Novo Nordisk Inc. v. Sun Pharmaceutical Indus. Ltd., No. 1:22-cv-00296-CFC, Dkt. 8 (D. Del. Mar. 16, 2022) Exhibit

EX2016 - Transfer Order, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC, Dkt. 1 (D. Del. Aug. 5, 2022) Exhibit

EX2014 - Excerpt of Redacted Patent Owner's Response, Mylan Pharms. Inc. v. Novo Nordisk A/S, IPR2023-00724, Pap.30 (Jan. 17, 2023) Exhibit

EX2012 - Summons in a Civil Action, Sun Pharmaceutical Industries, Inc., Novo Nordisk Inc. v. Sun Pharmaceutical Indus. Ltd., No. 1:22-cv-00296-CFC, Dkt. 7 (D. Del. Mar. 7, 2022) Exhibit

EX2025 - February 26, 2024 Email from C. Ferenc to M. Raymond, re: IPR2024-00107 Exhibit

EX2008 - Claim Construction Order, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC, Dkt. 148 (D. Del. July 25, 2023) Exhibit

EX2021 - Compilation of Rule 30(b)(1) Deposition Notices, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del.) Exhibit

Preliminary Response POPR

EX2010 - Excerpt of Novo Nordisk's Third Amended Disclosures to Defendants Sun Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries, Inc., In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC (D. Del. July 28, 2023) Exhibit

EX2027 - Joint Stipulation and Order Extending Deadline for Certain Fact Discovery, In re: Ozempic (Semaglutide) Patent Litigation, No. 22-MD-03038-CFC, Dkt. 305 (D. Del. Feb. 6, 2024) Exhibit

Notice: Notice filing date accorded NOTICE

Joint Stipulation Regarding Petitioners' Motion for Joinder OTHER

Petitioner's Updated Mandatory Notice NOTICE

Power of Attorney and Designation of Lead and Back-Up Counsel NOTICE

Patent Owner's Mandatory Notices NOTICE

Nielsen, Pharmacology of Exenatide (Synthetic Exendin-4): A Potential Thera Exhibit

Drucker, Enhancing Incretin Action for the Treatment of Type 2 Diabetes, 26 Exhibit

U.S. Patent No. 8,129,343 Exhibit

Landersdorfer, Mechanism-Based Population Pharmacokinetic Modelling in Diab Exhibit

Declaration of John Bantle, MD Exhibit

EMA, ICH Topic S 7 A Safety Pharmacology Studies for Human Pharmaceuticals Exhibit

Vilsbøll, Glucagon-Like Peptide-1 and Diabetes Treatment, 21 INT’L DIABETES Exhibit

Jimenez-Solem, Dulaglutide, a Long-Acting GLP-1 Analog Fused with an Fc Ant Exhibit

Tasneem, The Database for Aggregate Analysis of ClinicalTrials.gov (AACT) a Exhibit

ClinicalTrials.gov Background, CLINICALTRIALS.GOV, https://clinicaltrials.g Exhibit

Drucker, The Incretin System: Glucagon-Like Peptide-1 Receptor Agonists and Exhibit

WO 2011/138421 Exhibit

U.S. Patent No. 6,458,924 Exhibit

Ozempic prescribing information (Oct. 2022) Exhibit

Rohatagi, Model-Based Development of a PPARγ Agonist, Rivoglitazone, to Aid Exhibit

Rohatagi, Model-Based Development of a PPARγ Agonist, Rivoglitazone, to Aid Exhibit

Glaesner, Engineering and Characterization of the Long-Acting Glucagon-Like Exhibit

CV of Craig Dyar, Ph.D. Exhibit